title: ICV administration of anti-NPY antisense oligonucleotide: effects on feeding behavior, body weight, peptide content and peptide release.
abstract: Neuropeptide-Y (NPY) is a potent stimulator of feeding, and chronic administration of the peptide has been shown to increase body weight. This study determined the chronic effects of repeated daily injections of an antisense phosphorothioate oligonucleotide complementary to the rat mRNA for NPY (aNPY) on food intake, feeding behavior and body weight change in rats. Five micrograms of the aNPY oligonucleotide in ten microliters of vehicle or a missense control oligonucleotide were administered intracerebroventricularly (ICV) for seven consecutive days. Cumulative food intake, meal size and meal duration were significantly lowered in aNPY-treated animals. Body weight change of aNPY-injected animals was significantly lower than controls, and the effect was reversed after treatments ceased. A two-bottle taste aversion paradigm was employed to determine the behavioral specificity of the anorectic effect, and the phosphorothioate oligonucleotide was found not to be aversive at the dosage used. Following an additional five day injection period, animals were killed and paraventricular nuclei (PVN) were dissected. In vitro release and tissue content of NPY from this brain area were evaluated by heterologous radioimmunoassay. Content of NPY was unchanged in this brain area. Paradoxically, in vitro release of NPY was increased in aNPY-treated animals.
authors.affiliation: Department of Foods and Nutrition, College of Family and Consumer Sciences, University of Georgia, Athens 30602, USA.
authors.forename: M G
authors.initials: MG
authors.lastname: Hulsey
authors.forename: C M
authors.initials: CM
authors.lastname: Pless
authors.forename: B D
authors.initials: BD
authors.lastname: White
authors.forename: R J
authors.initials: RJ
authors.lastname: Martin
mesh_terms: D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects; D001483:Base Sequence; D001835:Body Weight / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical; D005247:Feeding Behavior / Q000187:drug effects*; D007276:Injections, Intraventricular; D008297:Male; D008969:Molecular Sequence Data; D009478:Neuropeptide Y / Q000235:genetics* / Q000378:metabolism; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013649:Taste / Q000502:physiology; D013873:Thionucleotides / Q000494:pharmacology*
chemical_list: D009478:Neuropeptide Y; D016376:Oligonucleotides, Antisense; D013873:Thionucleotides